Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: Potential role in tumor progression

Otology and Neurotology

Volumn 28, Issue 4, 2007, Pages 559-565

  Diensthuber, Marc ^a   Ilner, Torben ^a   Rodt, Thomas ^a   Samii, Madjid ^b   Brandis, Almuth ^a   Lenarz, Thomas ^a   Stöver, Timo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INTERNATIONAL NEUROSCIENCE INSTITUTE   (Germany)

Author keywords

Erythropoietin; Erythropoietin receptor; Hypoxia inducible factor 1 ; Immunohistochemistry; Microvessel density; Vestibular schwannoma

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; PROTEIN BCL 2; HIF1A PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NEURILEMOMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHWANN CELL; SEX DIFFERENCE; TUMOR VOLUME; VESTIBULAR DISORDER; VESTIBULAR SCHWANNOMA; BIOSYNTHESIS; CAPILLARY; DISEASE COURSE; EAR TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROSURGERY; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); NEUROMA; PATHOLOGY; PHYSIOLOGY; PROTO ONCOGENE;

ADOLESCENT; ADULT; AGED; CAPILLARIES; CELL PROLIFERATION; DISEASE PROGRESSION; EAR NEOPLASMS; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MICROSURGERY; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEUROMA, ACOUSTIC; RECEPTORS, ERYTHROPOIETIN; VESTIBULAR DISEASES;

EID: 34447643403     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/mao.0b013e3180423b05     Document Type: Article

References (31)

1. Patel NP, Mhatre AN, Lalwani AK. Molecular pathogenesis of skull base tumors. Otol Neurotol 2004;25:636-43.
2. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991;65:1097-8.
3. Diensthuber M, Lenarz T, Stöver T. Neurotrophic factor expression in vestibular schwannoma. Laryngorhinootologie 2006;85:731-7.
4. Li X, Gonias SL, Campana WM. Schwann cells express erythropoietin receptor and represent a major target for Epo in peripheral nerve injury. Glia 2005;51:254-65.
5. Tilbrook PA, Klinken SP. Erythropoietin and erythropoietin receptor. Growth Factors 1999;17:25-35.
6. Silva M, Grillot D, Benito A, et al. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996;88:1576-82.
7. Wojchowski DM, Gregory RC, Miller CP, et al. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999;253:143-56.
8. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994;91:3974-8.
9. Juul SE, Anderson DK, Li Y, et al. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998;43:40-9.
10. Conrad KP, Benyo DF, Westerhausen-Larsen A, et al. Expression of erythropoietin by the human placenta. FASEB J 1996;10:760-8.
11. Masuda S, Nagao M, Sasaki R. Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 1999;70:1-6.
12. Falcioni M, Taibah A, De Donato G. Fast-growing vestibular schwannoma. Skull Base Surg 2000;10:95-9.
13. Dillard DG, Venkatraman G, Cohen C, et al. Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma. Acta Otolaryngol 2001;121:149-52.
14. Diensthuber M, Brandis A, Lenarz T, et al. Co-expression of transforming growth factor-beta1 and glial cell line-derived neurotrophic factor in vestibular schwannoma. Otol Neurotol 2004;25:359-65.
15. Sasabe E, Tatemoto Y, Li D, et al. Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci 2005;96:394-402.
16. Chan CC, Chew EY, Shen D, et al. Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease. Mol Vis 2005;11:697-704.
17. Chleq-Deschamps CM, LeBrun DP, Huie P, et al. Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues. Blood 1993;81:293-8.
18. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003;162:1789-806.
19. Birner P, Gatterbauer B, Oberhuber G, et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 2001;92:165-71.
20. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001;93:309-14.
21. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-80.
22. Aguiar PH, Tatagiba M, Samii M, et al. The comparison between the growth fraction of bilateral vestibular schwannomas in neurofibromatosis2 (NF2)and unilateral vestibular schwannomas using the monoclonal antibody MIB 1. Acta Neurochir (Wien) 1995;134:40-5.
23. Acs G, Chen M, Xu X, et al. Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 2004;214:243-51.
24. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1864-77.
25. Jiang BH, Semenza GL, Bauer C, et al. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996;271:C1172-80.
26. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-6.
27. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
28. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7.
29. Welling DB, Lasak JM, Akhmametyeva E, et al. cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 2002;23:736-48.
30. Ribatti D, Vacca A, Roccaro AM, et al. Erythropoietin as an angiogenic factor. Eur J Clin Invest 2003;33:891-6.
31. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5.